Mirati Therapeutics (Mirati Therapeutics) Cash-to-Debt : 19.44 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Mirati Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2023 was 19.44.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Mirati Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Mirati Therapeutics's Cash-to-Debt or its related term are showing as below:

MRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 15.38 Med: No Debt Max: No Debt
Current: 19.44

During the past 13 years, Mirati Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 15.38. And the median was No Debt.

MRTX's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.49 vs MRTX: 19.44

Mirati Therapeutics Cash-to-Debt Historical Data

The historical data trend for Mirati Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mirati Therapeutics Cash-to-Debt Chart

Mirati Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

33.17

31.58

21.04

Mirati Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															23.43	21.04	17.65	15.38	19.44

Competitive Comparison of Mirati Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Mirati Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirati Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Mirati Therapeutics's Cash-to-Debt falls into.

Mirati Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Mirati Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1083.837	/	(7.844	+	43.661)
	=	21.04

Mirati Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	976.434	/	(8.02	+	42.203)
	=	19.44

Mirati Therapeutics (NAS:MRTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Mirati Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirati Therapeutics (Mirati Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

26M:Germany

Address

3545 Cray Court, San Diego, CA, USA, 92121

Website

https://www.mirati.com

Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.

Executives

Jamie Christensen	officer: Sr. Vice President, Chief Scie	C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey	officer: EVP, Chief Commercial Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey	officer: Interim CFO	3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang	other: See remarks	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake	other: See remarks	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty	officer: Chief Legal Officer	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer	officer: CFO	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington	director	9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121